Skip to main content

Advertisement

Log in

The burden of rheumatoid arthritis and access to treatment: health burden and costs

  • Original paper
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript

Abstract

As part of the study “The burden of rheumatoid arthritis and patient access to treatment”, this paper reviews evidence on the health burden of rheumatoid arthritis (RA) in terms of morbidity (DALYs), mortality (% of deaths attributable to RA) and quality of life (utility and loss of QALYs), as well as the economic impact on society. Based on available literature on the prevalence and the cost of RA, combined with economic indicators, the annual cost per patient as well as the total national cost is estimated for Europe and North America (Canada and the United States), as well as Australia, Turkey, the Russian Federation and South Africa. Total costs to society were estimated at €45.3 billion in Europe and at €41.6 billion in the United States. Utility scores were found to be amongst the lowest compared to other diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Silman, A.: Epidemiology of rheumatic diseases. Oxford University Press, Oxford (1993)

    Google Scholar 

  2. Centers for Disease Control and Prevention: Prevalence of arthritis—US 1997. MMWR 50, 334–336, [CD] (2001)

  3. Guillemin, F., Saraux, A., Guggenbuhl, P., et al.: Prevalence of rheumatoid arthritis in France: 2001. Ann. Rheum. Dis. 64, 1427–1430 (2005)

    Article  Google Scholar 

  4. Alamanos, Y., Voulgari, P.V., Drosos, A.A.: Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology Criteria: a systematic review. Semin. Arthritis Rheum. 36, 182–188 (2006)

    Article  Google Scholar 

  5. Andrianakos, A., Trontzas, P., Christoyannis, F., et al.: Prevalence of rheumatic diseases in Greece: a cross-sectional population-based epidemiological study. The ESORDIG Study. J. Rheumatol. 30, 1589–1601 (2003)

    Google Scholar 

  6. Carmona, L., Villaverde, V., Hernandez-Garcia, C., et al.: The prevalence of rheumatoid arthritis in the general population of Spain. Rheumatology (Oxford) 41(1), 88–95 (2002)

    Article  Google Scholar 

  7. Cimmino, M.A., Parisi, M., Moggiana, G., et al.: Prevalence of rheumatoid arthritis in Italy: the Chiavari Study. Ann. Rheum. Dis. 57, 315–318 (1998)

    Google Scholar 

  8. Drosos, A.A., Alamanos, I., Voulgari, P.V., et al.: Epidemiology of adult rheumatoid arthritis in northwest Greece 1987–1995. J. Rheumatol. 24, 2129–2133 (1997)

    Google Scholar 

  9. Saraux, A., Guedes, C., Allain, J., et al.: Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Societe de Rhumatologie de l’Ouest J. Rheumatol. 26, 2622–2627 (1999)

    Google Scholar 

  10. Gabriel, S.E., Crowson, C.S., O’Fallon, W.M.: The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955–1985. Arthritis Rheum. 42, 415–420 (1999)

    Article  Google Scholar 

  11. Hakala, M., Pollanen, R., Nieminen, P.: The ARA 1987 revised criteria select patients with clinical rheumatoid arthritis from a population based cohort of subjects with chronic rheumatic diseases registered for drug reimbursement. J. Rheumatol. 20, 1674–1678 (1993)

    Google Scholar 

  12. Power, D., Codd, M., Ivers, L., et al.: Prevalence of rheumatoid arthritis in Dublin, Ireland: a population based survey. Ir. J. Med. Sci. 168, 197–200 (1999)

    Article  Google Scholar 

  13. Riise, T., Jacobsen, B.K., Gran, J.T.: Incidence and prevalence of rheumatoid arthritis in the county of Tromsö, northern Norway. J. Rheumatol. 27, 1386–1389 (2000)

    Google Scholar 

  14. Simonsson, M., Bergman, S., Jacobsson, L.T., et al.: The prevalence of rheumatoid arthritis in Sweden. Scand. J. Rheumatol. 28, 340–343 (1999)

    Article  Google Scholar 

  15. Symmons, D., Turner, G., Webb, R., et al.: The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 41, 793–800 (2002)

    Article  Google Scholar 

  16. Uhlig, T., Kvien, T.K., Glennas, A., et al.: The incidence and severity of rheumatoid arthritis, results from a county register in Oslo, Norway. J, Rheumatol, 25, 1078–1084 (1998)

    Google Scholar 

  17. Rasch, E., Hirsch, R., Paulose-Ram, R., Hochberg, M.: Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum. 48, 917–926 (2003)

    Article  Google Scholar 

  18. Drosos, A., et al.: Rheumatoid Arthritis in Greek and British patients: a comparative clinical, radiologic, and serologic study. Arthritis Rheum. 35, 745–748 (1992)

    Article  Google Scholar 

  19. Antoni, C., Maini, R., Grunke, M., et al.: Cooperative of QoL in Rheumatic disease: results of a survey among 6,000 patients across 11 European countries. Arthritis Rheum 46:ACR (abstract) (2002)

  20. WHO Death and DALY estimates for 2002 by cause for WHO Member States, http://www.who.int/healthinfo/statistics/bodgbddeathdalyestimates.xls

  21. Rupp, I., Boshuizen, H.C., Dinant, H.J., et al.: Disability and health-related quality of life among patients with rheumatoid arthritis: association with radiographic joint damage, disease activity, pain, and depressive symptoms. Scand. J. Rheumatol. 35, 175–181 (2006)

    Article  Google Scholar 

  22. Young, A., Wilkinson, P., Talamo, J., et al.: Socioeconomic deprivation and rheumatoid disease. What lessons for the health service? Ann. Rheum. Dis. 59, 794–799 (2000)

    Article  Google Scholar 

  23. Kobelt, G., Lindgren, P., Lindroth, Y., Jacobson, L., Eberhardt, K.: Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford) 44, 1169–1175 (2005)

    Article  Google Scholar 

  24. Kobelt, G., Richard, B., Peeters, P., Sany, J.: Costs and quality of life of patients with RA in France. ACR 2006, Bone Joint Spine 75(7), (2008)

  25. Currie, C.J., McEwan, P., Peters, J.R., Patel, T.C., Dixon, S.: The routine collation of health outcomes data from hospital-treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health 8, 581–590 (2005)

    Article  Google Scholar 

  26. Orme, M., Kerrigan, J., Tyas, D., Russell, N., Nixon, R.: The effect of disease, functional status and relapses ont he utility of people with multiple sclerosis in the UK. Value Health 10, 54–60 (2007)

    Article  Google Scholar 

  27. Bloom, B.S., Bruno, D.J., Maman, D.Y., Jayadevappa, R.: Usefulness of US cost-of-illness studies in healthcare decision making. Pharmacoeconomics 19, 207–213 (2001)

    Article  Google Scholar 

  28. Koopmanschap, M.A.: Cost-of-illness studies. Useful for health policy? Pharmacoeconomics 14, 143–148 (1998)

    Article  Google Scholar 

  29. Cooper, N.J.: Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 39, 28–33 (2000)

    Article  Google Scholar 

  30. Pugner, K.M., Scott, D.I., Holmes, J.W., Hieke, K.: The costs of rheumatoid arthritis: an international long-term view. Semin. Arthritis Rheum. 29, 305–220 (2000)

    Article  Google Scholar 

  31. Rosery, H., Bergemann, R., Maxion-Bergemann, S.: International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review. Pharmacoeconomics 23, 243–257 (2005)

    Article  Google Scholar 

  32. Huscher, D., Merkesdal, S., Thiele, K., et al.: Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann. Rheum. Dis. 65, 1175–1183 (2006)

    Article  Google Scholar 

  33. Kirwan, J.R.: Conceptual issues in scoring radiographic progression in rheumatoid arthritis. J. Rheumatol. 26, 720–725 (1999)

    Google Scholar 

  34. Landewe, R.B., Boers, M., Verhoeven, A.C., et al.: COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 46, 347–356 (2002)

    Article  Google Scholar 

  35. Kobelt, G., Jonsson, L., Lindgren, P., et al.: Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum. 46, 2310–2319 (2002)

    Article  Google Scholar 

  36. Verstappen, S.M., Verkleij, H., Bijlsma, J.W., et al.: Determinants of direct costs in Dutch rheumatoid arthritis patients. Ann. Rheum. Dis. 63, 817–824 (2004)

    Article  Google Scholar 

  37. Hallert, E., Husberg, M., Skogh, T.: Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project). Rheumatology (Oxford) 45, 325–331 (2006)

    Article  Google Scholar 

  38. Michaud, K., Messer, J., Choi, H.K., Wolfe, F.: Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum. 48, 2750–2762 (2003)

    Article  Google Scholar 

  39. Kobelt, G., Eberhardt, K., Jonsson, L., Jonsson, B.: Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum. 42, 347–356 (1999)

    Article  Google Scholar 

  40. Hulsemann, J.L., Ruof, J., Zeidler, H., Mittendorf, T.: Costs in rheumatology: results and lessons learned from the ‘Hannover Costing Study’. Rheumatol. Int. 26, 704–711 (2006)

    Article  Google Scholar 

  41. Lajas, C., Abasolo, L., Bellajdel, B., et al.: Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum. 49, 64–70 (2003)

    Article  Google Scholar 

  42. Albers, J.M., Kuper, H.H., van Riel, P.L., et al.: Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Rheumatology (Oxford) 38, 423–430 (1999)

    Article  Google Scholar 

  43. Merkesdal, S., Ruof, J., Schoffski, O., et al.: Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum. 44, 528–534 (2001)

    Article  Google Scholar 

  44. Young, A., Dixey, J., Cox, N., et al.: How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology (Oxford) 39, 603–611 (2000)

    Article  Google Scholar 

  45. Fex, E., Larsson, B-M., Nived, K., Eberhardt, K.: Impact of rheumatoid arthritis on work status and social and leisure time activities in patients followed 8 years from onset. J. Rheumatol. 25, 44–50 (1997)

    Google Scholar 

  46. Merkesdal, S., Huelsemann, J.L., Mittendorf, T., et al.: Productivity costs of rhumatoid arthritis in Germany: cost composition and prediction of main cost components (in German). Z. Rheumatol. 65, 527–534 (2006)

    Article  Google Scholar 

  47. Chorus, A.M., Miedema, H.S., Wevers, C.J., van Der Linden, S.: Labour force participation among patients with rheumatoid arthritis. Ann. Rheum. Dis. 59, 549–554 (2000)

    Article  Google Scholar 

  48. Young, A., Dixey, J., Kulinskaya, E., et al.: Which patients with early RA stop working? Results from a 5-year inception cohort of 547 patients. Ann. Rheum. Dis. 61, 335–340 (2002)

    Article  Google Scholar 

  49. Meenan, R.F., Yelin, E.H., Henke, C.J., et al.: The costs of rheumatoid arthritis. A patient-oriented study of chronic disease costs. Arthritis Rheum. 21, 827–833 (1978)

    Article  Google Scholar 

  50. Liang, M.H., Larson, M., Thompson, M., et al.: Costs and outcomes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 27, 522–529 (1984)

    Article  Google Scholar 

  51. Lubeck, D.P., Spitz, P.W., Fries, J.F., et al.: A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum. 29, 488–493 (1986)

    Article  Google Scholar 

  52. Wolfe, F., Kleinheksel, S.M., Spitz, P.W., et al.: A multicenter study of hospitalization in rheumatoid arthritis. Frequency, medical-surgical admissions, and charges. Arthritis Rheum. 29, 614–619 (1986)

    Article  Google Scholar 

  53. Bloom, B.S.: Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am. J. Med. 84, 20–24 (1988)

    Article  Google Scholar 

  54. Gabriel, S.E., Crowson, C.S., Campion, M.E., O’Fallon, W.M.: Direct medical costs unique to people with arthritis. J. Rheumatol. 24, 719–725 (1997)

    Google Scholar 

  55. Gabriel, S.E., Crowson, C.S., Campion, M.E., O’Fallon, W.M.: Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J. Rheumatol. 24, 43–48 (1997)

    Google Scholar 

  56. Lanes, S.F., Lanza, L.L., Radensky, P.W., et al.: Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. Arthritis Rheum. 40, 1475–1481 (1997)

    Article  Google Scholar 

  57. Ward, M.M., Javitz, H.S., Yelin, E.H.: The direct cost of rheumatoid arthritis. Value Health 3, 243–252 (2000)

    Article  Google Scholar 

  58. Yelin, E.: The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J. Rheumatol. 44 (Suppl), 47–51 (1996)

    Google Scholar 

  59. Yelin, E., Wanke, L.A.: An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum. 42, 1209–1218 (1999)

    Article  Google Scholar 

  60. Andlin-Sobocki, P., Jonsson, B., Wittchen, H.U., Olesen, J.: Cost of disorders of the brain in Europe. Eur. J. Neurol. 12(Suppl 1), 1–27 (2005)

    Google Scholar 

  61. OECD health data (2006) OECD Geneva

  62. Eurostat (2006) Economy and finance, Brussels

  63. The Word Bank (2007) http://www.worldbank.org

  64. Kobelt, G., Berg, J., Lindgren, P., Fredrikson, S., Jönsson, B.: Costs and quality of life of multiple sclerosis in Europe. J. Neurol. Neurosurg. Psychiatry 77, 918–926 (2006)

    Article  Google Scholar 

  65. Wagner, E., Lackerbauer, E., Siegmeth, W.: Direct and indirect costs of rheumatoid arthritis and the socio-emotional effects of this disease—an Austrian study (in German). Wien Med Wochenschr 155, 217–226 (2005)

    Article  Google Scholar 

  66. Westhovens, R., Boonen, A., Verbruggen, L., et al.: Healthcare consumption and direct costs of rheumatoid arthritis in Belgium. Clin. Rheumatol. 24, 615–619 (2005)

    Article  Google Scholar 

  67. Maetzel, A., Li, L.C., Pencharz, J., et al.: The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann. Rheum. Dis. 63, 395–401 (2004)

    Article  Google Scholar 

  68. Sorensen, J.: Health care costs attributable to the treatment of rheumatoid arthritis. Scand. J. Rheumatol. 33, 399–404 (2004)

    Article  Google Scholar 

  69. Leardini, G., Salaffi, F., Montanelli, R., et al.: A multicenter cost-of-illness study on rheumatoid arthritis in Italy. Clin. Exp. Rheumatol. 20, 505–515 (2002)

    Google Scholar 

  70. Verstappen, S.M., Jacobs, J.W., van der Heijde, D.M., et al.: Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis. Ann. Rheum. Dis. (2006)

  71. Jacobsson, L.T., Lindroth, Y., Marsal, L., Juran, E., Bergstrom, U., Kobelt, G.: Rheumatoid arthritis: what does it cost and what factors are driving those costs? Results of a survey in a community-derived population in Malmo, Sweden. Scand. J. Rheumatol. 36, 179–183 (2007)

    Article  Google Scholar 

  72. Kobelt, G., Lindgren, P., Singh, A., Klareskog, L.: Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann. Rheum. Dis. 64, 1174–1179 (2005)

    Article  Google Scholar 

  73. McIntosh, E.: The cost of rheumatoid arthritis. Br. J. Rheumatol. 35, 781–790 (1996)

    Article  Google Scholar 

  74. Sobocki, P., Pugliatti, M., Lauer, L., Kobelt, G.: Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Mult. Scler. 13, 1054–1064 (2007)

    Article  Google Scholar 

Download references

Conflict of interest

This study has been funded by unrestricted grant from F. Hoffmann-La Roche Ltd., Basel, Switzerland.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J. Lundkvist.

Additional information

It should be noted that the studies on which the estimates are based were conducted at different points in time. As noted earlier, drugs costs have likely increased over time, in particular after the introduction of the new biological agents. Also, informal care costs are based on limited data.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lundkvist, J., Kastäng, F. & Kobelt, G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 8 (Suppl 2), 49–60 (2008). https://doi.org/10.1007/s10198-007-0088-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-007-0088-8

Keywords

JEL Classification

Navigation